Categories
Blood Cancer

Advances in CAR-T therapy for R/R multiple myeloma: ide-cel & cilta-cel [Video]

Advances in CAR-T therapy for R/R multiple myeloma: ide-cel & cilta-cel

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the efficacy and promise of BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory (R/R) multiple myeloma. Ide-cel was approved in March 2021 for patients with R/R multiple myeloma based on the results of the Phase II KarMMA study (NCT03361748) which reported a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months. The field of CAR-T therapies for multiple myeloma is rapidly evolving, notably with cilta-cel, which showed remarkable results in the Phase Ib/II CARTITUDE-1 trial (NCT03548207), with an overall response rate (ORR) of almost 98% and a 2-year PFS of 71%. In addition, the incidence of severe cytokine release syndrome (CRS) and neurotoxicity was low. These trials highlight the potency of BCMA-directed CAR-T therapies for R/R multiple myeloma and several clinical trials are now evaluating these approaches in earlier lines of treatment. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Watch/Read More
Categories
Blood Cancer

The role of selinexor in the treatment of multiple myeloma [Video]

In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of selinexor in the treatment of multiple myeloma, emphasizing its value in patients with del(17p)-positive relapsed/refractory (R/R) disease. Dr Richardson also highlights some of the challenges associated with the use of selinexor, and clinical trials evaluating the safety and efficacy of this agent. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

New ProPublica investigation reveals racist environmental "sacrifice zones" [Video]

In a new investigation, ProPublica reporters Lylla Younes, Ava Kofman, Al Shaw, Lisa Song, and Maya Miller used EPA data processing software to examine the spread of cancer-causing chemicals and other hazardous air pollutions in communities across the United States. At the maps intimate scale, its possible to see up close how a massive chemical

Categories
Blood Cancer

How Long will a Patient Remain in the Hospital after CAR-T Reinfusion? [Video]

HealthTree University, provided by the HealthTree Foundation, offers a comprehensive online multiple myeloma curriculum with lessons, quizzes and course discussion. Learn for free at https://www.healthtree.org. Topics covered include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much more. We've partnered with over 100 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.Follow HealthTree:Twitter: https://www.twitter.com/healthtreeformmFacebook: https://www.facebook.com/healthtreeformultiplemyelomaInstagram: https://www.instragram.com/healthtreeformultiplemyeloma